The global coagulation testing market accounted for USD 3.95 billion in 2023 and is expected to reach USD 13.10 billion by 2034 with a CAGR of 11.52% during the forecast period 2024-2034. The market will grow due to growing awareness and screening programs, growing incidence of hemostasis disorders, technological advancements, growing need for point-of-care testing, and strategic alliances and collaborations.
More sensitive, accurate, and user-friendly coagulation testing equipment and assays have been made possible by technological advancements. The efficiency and dependability of coagulation tests have increased due to technological improvements, which have increased their accessibility and appeal to healthcare professionals. For instance, in April 2022, Varian Medical Systems, a pioneer in cancer care solutions, was to be acquired by Siemens Healthineers. Radiation oncology and cutting-edge cancer care were added to Siemens Healthineers' offering with this acquisition.
By product, the consumables segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of consumables such as reagents, test kits, and control materials for routine coagulation testing procedures across healthcare facilities worldwide. For instance, Abbott reported in March 2022 that the FDA had cleared their ARCHITECT STAT High-Sensitivity Troponin-I blood test. This test improves the diagnostic accuracy of heart attacks, allowing medical personnel to quickly identify people who are at high risk. Additionally, the instruments segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for advanced coagulation testing instruments with enhanced features such as automation, high throughput, and improved accuracy, especially in laboratories and point-of-care settings.
By test, the prothrombin time segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increased prevalence of conditions requiring prothrombin time testing, such as liver disease, vitamin K deficiency, and anticoagulant therapy monitoring, driving its usage across various healthcare settings. For instance, in January 2022, Mesa Biotech, Inc. - a supplier of molecular diagnostic testing solutions for infectious diseases, including COVID-19 - was fully acquired by Thermo Fisher Scientific. Additionally, the other tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of coagulation testing beyond traditional assays, including novel biomarker testing for thrombosis risk assessment and personalized medicine, driving demand for diversified testing options.
By technology, the optical technology segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of optical technologies such as turbidimetry and chromogenic assays for their high sensitivity, specificity, and rapid results, particularly in laboratory settings. For instance, Danaher stated in March 2022 that it had successfully completed the acquisition of Aldevron, a market leader in the production of proteins, antibodies, and nucleic acids for the biotechnology sector. Additionally, the electrochemical technology segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for portable and user-friendly coagulation testing devices utilizing electrochemical technology, offering rapid results and suitability for point-of-care settings.
By application, the activated partial thromboplastin time segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increased utilization of activated partial thromboplastin time (APTT) testing for monitoring heparin therapy, assessing coagulation disorders, and diagnosing hemophilia, driving its prominence in the market. For instance, Bio-Rad announced in January 2022 the introduction of EQ Power Reagents, a new line of reagents designed to be used with the company's BioPlex 2200 system. Improved sensitivity and specificity for testing for autoimmune diseases are offered by these reagents. Additionally, the activated clotting time (ACT) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for activated clotting time (ACT) testing in intraoperative and interventional procedures, especially in cardiac surgeries and interventional cardiology, driving its accelerated growth in the market.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of coagulation testing for diagnosis, monitoring, and management of various hemostasis disorders and thrombotic conditions in hospital settings, driving its revenue growth. For instance, Diagnostica Stago announced in February 2022 the release of the STA Compact Max 4, a new completely automated coagulation analyzer. Advanced features are available for both standard and specialized coagulation testing with this analyzer. Additionally, the point-of-care testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for rapid and decentralized coagulation testing solutions in emergency departments, clinics, and physician offices, driving the accelerated growth of the point-of-care testing segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, increasing prevalence of coagulation disorders, high adoption rate of advanced coagulation testing technologies, and supportive reimbursement policies, driving the dominance of the North American region in the global coagulation testing market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about early diagnosis and management of coagulation disorders, increasing healthcare expenditure, and growing focus of market players on expanding their presence in emerging economies, driving the robust growth of the Asia Pacific region in the global coagulation testing market. For instance, Nihon Kohden announced in February 2023 the release of the CA-1200, a revolutionary coagulation analyzer with better automation and improved usability for laboratory coagulation testing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
More sensitive, accurate, and user-friendly coagulation testing equipment and assays have been made possible by technological advancements. The efficiency and dependability of coagulation tests have increased due to technological improvements, which have increased their accessibility and appeal to healthcare professionals. For instance, in April 2022, Varian Medical Systems, a pioneer in cancer care solutions, was to be acquired by Siemens Healthineers. Radiation oncology and cutting-edge cancer care were added to Siemens Healthineers' offering with this acquisition.
By product, the consumables segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of consumables such as reagents, test kits, and control materials for routine coagulation testing procedures across healthcare facilities worldwide. For instance, Abbott reported in March 2022 that the FDA had cleared their ARCHITECT STAT High-Sensitivity Troponin-I blood test. This test improves the diagnostic accuracy of heart attacks, allowing medical personnel to quickly identify people who are at high risk. Additionally, the instruments segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for advanced coagulation testing instruments with enhanced features such as automation, high throughput, and improved accuracy, especially in laboratories and point-of-care settings.
By test, the prothrombin time segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increased prevalence of conditions requiring prothrombin time testing, such as liver disease, vitamin K deficiency, and anticoagulant therapy monitoring, driving its usage across various healthcare settings. For instance, in January 2022, Mesa Biotech, Inc. - a supplier of molecular diagnostic testing solutions for infectious diseases, including COVID-19 - was fully acquired by Thermo Fisher Scientific. Additionally, the other tests segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding applications of coagulation testing beyond traditional assays, including novel biomarker testing for thrombosis risk assessment and personalized medicine, driving demand for diversified testing options.
By technology, the optical technology segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of optical technologies such as turbidimetry and chromogenic assays for their high sensitivity, specificity, and rapid results, particularly in laboratory settings. For instance, Danaher stated in March 2022 that it had successfully completed the acquisition of Aldevron, a market leader in the production of proteins, antibodies, and nucleic acids for the biotechnology sector. Additionally, the electrochemical technology segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for portable and user-friendly coagulation testing devices utilizing electrochemical technology, offering rapid results and suitability for point-of-care settings.
By application, the activated partial thromboplastin time segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increased utilization of activated partial thromboplastin time (APTT) testing for monitoring heparin therapy, assessing coagulation disorders, and diagnosing hemophilia, driving its prominence in the market. For instance, Bio-Rad announced in January 2022 the introduction of EQ Power Reagents, a new line of reagents designed to be used with the company's BioPlex 2200 system. Improved sensitivity and specificity for testing for autoimmune diseases are offered by these reagents. Additionally, the activated clotting time (ACT) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for activated clotting time (ACT) testing in intraoperative and interventional procedures, especially in cardiac surgeries and interventional cardiology, driving its accelerated growth in the market.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global coagulation testing market in 2023 owing to the increasing adoption of coagulation testing for diagnosis, monitoring, and management of various hemostasis disorders and thrombotic conditions in hospital settings, driving its revenue growth. For instance, Diagnostica Stago announced in February 2022 the release of the STA Compact Max 4, a new completely automated coagulation analyzer. Advanced features are available for both standard and specialized coagulation testing with this analyzer. Additionally, the point-of-care testing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for rapid and decentralized coagulation testing solutions in emergency departments, clinics, and physician offices, driving the accelerated growth of the point-of-care testing segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of well-established healthcare infrastructure, increasing prevalence of coagulation disorders, high adoption rate of advanced coagulation testing technologies, and supportive reimbursement policies, driving the dominance of the North American region in the global coagulation testing market. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about early diagnosis and management of coagulation disorders, increasing healthcare expenditure, and growing focus of market players on expanding their presence in emerging economies, driving the robust growth of the Asia Pacific region in the global coagulation testing market. For instance, Nihon Kohden announced in February 2023 the release of the CA-1200, a revolutionary coagulation analyzer with better automation and improved usability for laboratory coagulation testing.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Test, Technology, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Coagulation Testing Market Report 2023 - 2034
Coagulation Testing Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Instruments
- Consumables
- Reagents and Standards
- Controls
- Calibrations
Coagulation Testing Market Analysis & Forecast by Test 2023 - 2034 (Revenue USD Bn)
- Prothrombin Time
- Platelet Count
- Thrombin Time
- Bleeding Time
- Complete Blood Count (CBC)
- Factor V Assay
- Fibrinogen Level
- Others
Coagulation Testing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Optical Technology
- Mechanical Technology
- Electrochemical Technology
- Others
Coagulation Testing Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Activated Clotting Time (ACT)
- Thrombin Time (TT)
- Partial Thromboplastin Time (PTT)
- Activated Partial Thromboplastin Time (APTT)
- Prothrombin Time (PT)
- Other Tests
Coagulation Testing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Clinical Laboratories
- Point-of-Care Testing
- Others
Coagulation Testing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Coagulation Testing Market: Product Estimates & Trend Analysis
8. Coagulation Testing Market: Test Estimates & Trend Analysis
9. Coagulation Testing Market: Technology Estimates & Trend Analysis
10. Coagulation Testing Market: Application Estimates & Trend Analysis
11. Coagulation Testing Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Coagulation Testing Market
14. Europe Global Coagulation Testing Market
15. Asia Pacific Global Coagulation Testing Market
16. Latin America Global Coagulation Testing Market
17. MEA Global Coagulation Testing Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Siemens Healthineers. F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Instrumentation Laboratory (Werfen)
- Nihon Kohden Corporation
- Helena Laboratories Corporation
- Bio-Rad Laboratories Inc.
- Diagnostica Stago
- International Technidyne Corporation (ITC)
- HemoSonics LLC
- CoaguSense Inc.
- Tcoag Ireland Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.95 Billion |
| Forecasted Market Value ( USD | $ 13.1 Billion |
| Compound Annual Growth Rate | 11.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
